27 March,2021 03:45 PM IST | New Delhi | IANS
Serum Institute of India`s CEO Adar Poonawalla gestures during a press conference in Pune. Pic/AFP
Serum Institute of India, the world's biggest Covid-19 vaccine maker, is hopeful to launch Covovax by September this year, CEO Adar Poonawalla announced on Saturday.
"Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India," said Adar Poonawalla.
He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent. "Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.
Covovax is the protein-based Covid-19 vaccine developed by Novavax, headquartered in the US.
ALSO READ
Bengaluru: Case registered in connection with COVID-19 mismanagement
Biden commutes roughly 1,500 sentences, pardons 39
Morocco produces Africa’s first test kits to fight Mpox
Covid virus lurks in skull and brain meninges for years after infection: Study
‘Misguided, forced to take Covid vaccines’
In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
